Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07015242 · ClinicalTrials.gov registry record · Phase 2
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
A Phase 2 study of Lymphoma, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
- 20
- Study locations
NCT07015242 is a Phase 2 study of Lymphoma that is actively recruiting participants, run by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. The registered enrollment target is 65 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT07015242, a Phase 2 study of Lymphoma, is actively recruiting participants, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).
Conditions Studied
Interventions
- DRUG Rituximab
- DRUG Temozolomide
- DRUG Methotrexate
- DRUG Procarbazine
- BIOLOGICAL Liso-cel
Study Locations (20)
New York
- Local Institution - 310 - Buffalo
- Roswell Park Comprehensive Cancer Center - Buffalo
- Local Institution - 301 - New York
- Memorial Sloan Kettering Cancer Center - New York
Massachusetts
- Local Institution - 314 - Boston
- Dana-Farber Cancer Institute - Boston
- Local Institution - 313 - Boston
Colorado
- Local Institution - 0305 - Aurora
- Local Institution - 305 - Aurora
Florida
- Local Institution - 308 - Tampa
- Moffitt Cancer Center - Tampa
Illinois
- Local Institution - 0311 - Chicago
- Local Institution - 311 - Chicago
Missouri
- Local Institution - 316 - St Louis
- Washington University School of Medicine in St. Louis - St Louis
New Jersey
- Local Institution - 0315 - New Brunswick
- Local Institution - 315 - New Brunswick
Ohio
- Cleveland Clinic - Cleveland
- Local Institution - 302 - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2025-11-06 |
| Est. Completion | 2028-12-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07015242
The ClinicalTrials.gov registry entry for NCT07015242 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (87% lower). The listed sponsor is Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Rituximab is the first listed.
NCT07015242 reports 20 study locations spanning 9 distinct geographic areas - top geographies include New York, Massachusetts, Colorado.
Frequently Asked Questions
What is clinical trial NCT07015242 about?
NCT07015242 is a clinical study titled "A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma". The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).
What is the current status of trial NCT07015242?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2025-11-06. Estimated completion is 2028-12-10.
What conditions does trial NCT07015242 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT07015242?
The interventions under investigation include: Rituximab (DRUG), Temozolomide (DRUG), Methotrexate (DRUG), Procarbazine (DRUG), Liso-cel (BIOLOGICAL).
Who is sponsoring clinical trial NCT07015242?
This trial is sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07015242 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.